Delcath Systems, Inc. (DCTH) Stock Score, Valuation & Financial Research
Delcath Systems, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 40/100.
Quick answer for DCTH
Delcath Systems, Inc. currently has a Wall Street Score of 40/100. The stored market price is $16.22. Its financial score is 72/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Delcath Systems, Inc. does
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical cen
DCTH financial snapshot
- Wall Street Score:
- 40/100
- Current price:
- $16.22
- Market capitalization:
- $559.9M
- Revenue:
- $95.4M
- Net income:
- $532K
- Free cash flow:
- $21.0M
- Cash:
- $47.5M
- Total debt:
- $2.5M
- EPS:
- 0.01
- P/E ratio:
- 1474.5x
- Financial score:
- 72/100
- Valuation score:
- 0/100
- Revenue score:
- 34/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $21.0M, showing positive cash generation.
- The balance sheet shows $47.5M of cash versus $2.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 72/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research DCTH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.